Biotech company Stem Cell Medicine (SCM) has announced that it licensed intranasal MSC-exo technology for the treatment of autism spectrum disorder (ASD) from Ramot, the Tel Aviv University Business Engagement Center.
SCM Chairman Ehud Marom commented, “Intranasal administration is especially suitable for pediatric ASD patients and, based on the encouraging results we have seen to date with the MSC-exo technology, we are committed to investing in this treatment. This is an important part of SCM’s focus and this program is consistent with our goal to bring novel treatments for neurological conditions, including autism, to market. SCM is rapidly progressing from pre-clinical activities to the clinical development. We plan to fund the program by raising $30 million through partnerships and investment.”
Read the SCM press release.
